September 17, 2019 | English | عربي
Add to Twitter
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound
• Boehringer Ingelheim strengthens its pipeline portfolio for patients with gastrointestinal and lung cancers with this new licensing, development and commercialization agreement

• Lupin’s proprietary MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s emerging KRAS inhibitor pipeline to address KRAS-driven cancers

• Lupin to receive a $20 million upfront payment with potential total milestones of more than $700 million and royalties on the sales of the product